WuXi and Lilly Collaborate to Develop Novel Therapeutics in China

We are pleased to share with you that we have entered into a strategic collaboration with Eli Lilly and Company to develop, manufacture and commercialize a novel small molecule in China...

WuXi and MedImmune Form a Strategic Alliance to Develop Innovative Biologics in China for...

We are pleased to announce that we have formed a strategic alliance with MedImmune, the global biologics research and development arm of AstraZeneca to bring cutting-edge research and technical capability for...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Acquires ResearchPoint Global to Better Enable Clinical Development Worldwide

We are pleased to announce that WuXi has acquired ResearchPoint Global (RPG), a U..S-based contract research organization (CRO) with expertise spanning across all major...